The sphingolipid inhibitor myriocin increases Candida auris susceptibility to amphotericin B

Abstract Background The emergence of the pathogenic yeast Candida auris is of global concern due to its ability to cause hospital outbreaks and develop resistance against all antifungal drug classes. Based on published data for baker's yeast Saccharomyces cerevisiae , sphingolipid biosynthesis, which is essential for maintaining membrane fluidity and formation of lipid rafts, could offer a target for additive treatment. Methods We analysed the susceptibility of C . auris to myriocin, which is an inhibitor of the de novo synthesis of sphingolipids in eukaryotic cells in comparison to other Candida species. In addition, we combined sublethal concentrations of myriocin with the antifungal drugs amphotericin B and fluconazole in E ‐tests. Consequently, the combinatory effects of myriocin and amphotericin B were examined in broth microdilution assays. Results Myriocin‐mediated inhibition of the sphingolipid biosynthesis affected the growth of C . auris . Sublethal myriocin concentrations increased fungal susceptibility to amphotericin B. Isolates which are phenotypically resistant (≥2 mg/L) to amphotericin B became susceptible in presence of myriocin. However, addition of myriocin had only limited effects onto the susceptibility of C . auris against fluconazole. Conclusions Our results show that inhibition of de novo sphingolipid biosynthesis increases the susceptibility of C . auris to amphotericin B. This may potentially enhance antifungal treatment options fighting this often resistant yeast pathogen.